Skip to main content

Table 4 Univariate analysis of survival after surgery

From: Long-term outcomes and prognostic factor analysis of resected Siewert type II adenocarcinoma of esophagogastric junction in China: a seven-year study

Variables MST (month) Univariate analysis P-value
HR 95% CI
Gender (male vs. female) 62.4 vs. NA 1.608 1.019–2.539 0.039
Pathology (adeno vs. mix) 85.4 vs. 42.5 0.632 0.442–0.903 0.011
Blood transfusion (no vs. yes) 12.4 vs. 81.8 0.262 0.156–0.440 < 0.001
Surgical approaches (left thoracotomy vs. transhiatal) 42.5 vs. 87.6 1.569 1.110–2.218 < 0.001
Tumor size (≤ 4cm vs. >4cm) NA vs. 43.8 0.41 0.274–0.616 < 0.001
 Adjuvant chemotherapy (no vs. yes) 61.7 vs. 93.4 1.477 1.042–2.094 0.027
 Postoperative hospital stays (≤ 10d vs. > 10d) 59.9 vs. 99.7 0.806 0.680-0.956 0.012
 Type of gastric resection (total vs. proximal) 73.5 vs. 64.5 0.96 0.811–1.135 0.63
PNLNR
 = 0 NA 0.403 0.298–0.543  
 ≤ 1 67.2 0.772 0.613–0.972  
 > 1 11.8 1 1  
Perineuronal invasion (no vs. yes) NA vs. 48.1 0.454 0.310–0.664 < 0.001
Lymphovascular invasion (no vs. yes) NA vs. 40.9 0.448 0.317–0.634 < 0.001
Differentiation 80 vs. 73 vs. 63    0.851
pTNM stage     < 0.001
 I 97.4 0.253 0.121–0.526  
 II 99.7 0.265 0.155–0.451  
 III 119.56 0.364 0.248–0.533  
 IV 24.5 1 1  
Serum CA199 (U/ml) (< 37 vs. ≥ 37) 93.4 vs. 31.7 0.784 0.654–0.939 0.008
Serum CEA (ng/ml) (< 5 vs. ≥5) 80.0 vs. 26.3 0.74 0.623–0.878 < 0.001
Serum CA242 (U/ml) (< 20 vs. ≥20) 73.0 vs. 12.0 0.746 0.596–0.934 0.01
Serum CA125 (U/ml) (< 35 vs. ≥35) 71.4 vs. 70.1 0.605 0.423–0.866 0.004
Serum AFP (ng/ml) (< 10 vs. ≥10) 80.3 vs. 51.1 1.067 0.761–1.496 0.706
Serum CA724 (U/ml) (< 6.9 vs. ≥6.9) 70.1 vs. 80.0 0.862 0.715–1.039 0.117
Serum ferritin (ng/ml) (< 274.66 vs. ≥274.66)   0.952 0.708–1.280 0.745